Influenza

Phase II Study of Pandemic Influenza Vaccine

NCT00320346 | PHASE 2 | INTERVENTIONAL

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic. This study will test the safety and immunogenicity of a H5N1 Pandemic Influenza Vaccine in healthy adults. The Study will also assess Lot to Lot consistency of the Pandemic Influenza Vaccine.

3 Sites

400 Participants

Recruiting

18 Years to 64 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

CMAX, a division of IDT Australia

Adelaide,South Australia,Australia

Murdoch Childrens Research Institute

Melbourne,Victoria,Australia,3052

Princess Margaret Hospital for Children

Perth,Western Australia,Australia

Study Eligibility Criteria

Inclusion Criteria

* Healthy Adults

Exclusion Criteria

* Previous vaccination with an influenza Vaccine containing the H5N1 strain
* History of clinically significant medical conditions
* History of Guillian-Barre Syndrome or active Neurological disease

Additional Studies

Additional studies can be found at ClinicalTrials.gov